Cellular Therapy for In Utero Repair of Myelomeningocele (the CuRe trial): neurosurgical repair video

The Management of Myelomeningocele Study (MOMS) established that prenatal repair of myelomeningocele (MMC) improved the rate of ventriculoperitoneal shunt insertion for the treatment of hydrocephalus, compared to postnatal repair. While there was mild improvement of motor function, most children were unable to ambulate independently. Therefore, the ongoing phase 1/2a clinical trial Cellular Therapy for In Utero Repair of Myelomeningocele (CuRe trial) aims to further improve distal neurological function using placenta-derived mesenchymal stem/stromal cells seeded on an extracellular matrix (PMSC-ECM) to augment open fetal repair of MMC. Here, the authors present a video of the neurosurgical repair using the PMSC-ECM. The video can be found here: https://stream.cadmore.media/r10.3171/2026.1.FOCVID25229.